{
    "organizations": [],
    "uuid": "ec60d00e566c74942884eab2122bf89f3879d1bd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fibrocell-announces-fda-allowance/brief-fibrocell-announces-fda-allowance-of-investigational-new-drug-application-for-fcx-013-idUSASB0C8YC",
    "ord_in_thread": 0,
    "title": "BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Fibrocell Science Inc:\n* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA\n* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA\n* FIBROCELL SCIENCE - U.S. FDA GRANTED IND APPLICATION FOR FCX-013 TO BEGIN CLINICAL TRIALS FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA\n* FIBROCELL SCIENCE - EXPECTS TO INITIATE ENROLLMENT FOR OPEN LABEL, SINGLE ARM PHASE 1/2 CLINICAL TRIAL IN Q3 2018 FOR FCX-013\n* FIBROCELL SCIENCE- INTENDS TO INCLUDE PEDIATRIC PATIENTS IN PHASE 2 POST APPROVAL OF SAFETY AND ACTIVITY DATA FROM ADULT PHASE 1 PATIENTS TO FDA Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-03-06T21:18:00.000+02:00",
    "crawled": "2018-03-07T19:25:04.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "fibrocell",
        "science",
        "inc",
        "fibrocell",
        "announces",
        "fda",
        "allowance",
        "investigational",
        "new",
        "drug",
        "application",
        "treatment",
        "moderate",
        "severe",
        "localized",
        "scleroderma",
        "fibrocell",
        "announces",
        "fda",
        "allowance",
        "investigational",
        "new",
        "drug",
        "application",
        "treatment",
        "moderate",
        "severe",
        "localized",
        "scleroderma",
        "fibrocell",
        "science",
        "fda",
        "granted",
        "ind",
        "application",
        "begin",
        "clinical",
        "trial",
        "treatment",
        "moderate",
        "severe",
        "localized",
        "scleroderma",
        "fibrocell",
        "science",
        "expects",
        "initiate",
        "enrollment",
        "open",
        "label",
        "single",
        "arm",
        "phase",
        "clinical",
        "trial",
        "q3",
        "fibrocell",
        "intends",
        "include",
        "pediatric",
        "patient",
        "phase",
        "post",
        "approval",
        "safety",
        "activity",
        "data",
        "adult",
        "phase",
        "patient",
        "fda",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}